CL2021003153A1 - Antibióticos macrocíclicos de amplio espectro - Google Patents

Antibióticos macrocíclicos de amplio espectro

Info

Publication number
CL2021003153A1
CL2021003153A1 CL2021003153A CL2021003153A CL2021003153A1 CL 2021003153 A1 CL2021003153 A1 CL 2021003153A1 CL 2021003153 A CL2021003153 A CL 2021003153A CL 2021003153 A CL2021003153 A CL 2021003153A CL 2021003153 A1 CL2021003153 A1 CL 2021003153A1
Authority
CL
Chile
Prior art keywords
broad
compounds
spectrum
macrocyclic antibiotics
spectrum macrocyclic
Prior art date
Application number
CL2021003153A
Other languages
English (en)
Inventor
Peter Andrew Smith
Michael Friedrich Thomas Koehler
Dana Winter
Boubacar Sow
Claudio Sturino
Guillaume Pelletier
Jonathan Boudreault
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2021003153A1 publication Critical patent/CL2021003153A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C07D245/02—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)

Abstract

Se proporcionan en la presente compuestos antibacterianos, en donde los compuestos en algunas formas de realización tienen bioactividad de amplio espectro. En diversas formas de realización, los compuestos actúan mediante la inhibición de las peptidasas señal de tipo 1 bacteriana SpsB y/o LepB, una proteína esencial en bacterias. Se proporcionan además composiciones farmacéuticas y métodos de tratamiento mediante el uso de los compuestos descritos en la presente.
CL2021003153A 2019-05-28 2021-11-26 Antibióticos macrocíclicos de amplio espectro CL2021003153A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962853457P 2019-05-28 2019-05-28

Publications (1)

Publication Number Publication Date
CL2021003153A1 true CL2021003153A1 (es) 2022-07-29

Family

ID=73551292

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021003153A CL2021003153A1 (es) 2019-05-28 2021-11-26 Antibióticos macrocíclicos de amplio espectro

Country Status (30)

Country Link
US (2) US11208387B2 (es)
EP (2) EP3968983B1 (es)
JP (2) JP7078807B2 (es)
KR (2) KR102450071B1 (es)
CN (2) CN115215923A (es)
AR (1) AR119019A1 (es)
AU (2) AU2020282975B2 (es)
BR (1) BR112021024010A2 (es)
CA (1) CA3141853A1 (es)
CL (1) CL2021003153A1 (es)
CO (1) CO2021017561A2 (es)
CR (1) CR20210682A (es)
DK (1) DK3968983T3 (es)
ES (1) ES2961566T3 (es)
FI (1) FI3968983T3 (es)
HR (1) HRP20231497T1 (es)
HU (1) HUE063847T2 (es)
IL (2) IL295889A (es)
LT (1) LT3968983T (es)
MA (1) MA55981B1 (es)
MX (1) MX2021014554A (es)
NZ (1) NZ783605A (es)
PE (2) PE20230383A1 (es)
PL (1) PL3968983T3 (es)
PT (1) PT3968983T (es)
RS (1) RS64852B1 (es)
SG (1) SG11202112920SA (es)
SI (1) SI3968983T1 (es)
TW (2) TWI815017B (es)
WO (1) WO2020243155A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6873993B2 (ja) 2015-11-20 2021-05-19 アールキューエックス ファーマシューティカルズ，インク． 大環状広域抗生物質
KR102602837B1 (ko) * 2021-03-08 2023-11-15 차의과학대학교 산학협력단 항독력활성을 가지는 화합물
CN113583003A (zh) * 2021-08-05 2021-11-02 广东西捷药业有限公司 一种伐地那非类似物及其合成方法和应用
CN113933416B (zh) * 2021-09-30 2023-10-10 海南海灵化学制药有限公司 一种注射用硫酸头孢匹罗中杂质的检测方法
WO2024102404A1 (en) 2022-11-11 2024-05-16 Genentech, Inc. Enzymatic asymmetric syntheses of n-alkyl amino acids

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3128280A (en) 1959-10-23 1964-04-07 Searle & Co 1-(alkoxylated/halogenated phenyl)-3-pyridylmethylureas
US5204328A (en) 1990-06-26 1993-04-20 Merck & Co., Inc. Peptides having atrial natriuretic factor activity
JPH11514527A (ja) 1995-11-03 1999-12-14 イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー バキルス エスピー（Ｂａｃｉｌｌｕｓ ｓｐ．）用の陽性選択ベクター
PL194025B1 (pl) 1996-10-18 2007-04-30 Vertex Pharma Inhibitory proteaz serynowych, a zwłaszcza proteazy wirusa NS3 zapalenia wątroby C, kompozycja farmaceutyczna i zastosowanie inhibitorów proteaz serynowych
EP0895999A1 (en) 1997-08-06 1999-02-10 Pfizer Products Inc. C-4" substituted macrolide antibiotics
GB9902399D0 (en) 1999-02-03 1999-03-24 Smithkline Beecham Plc Compounds
US6660832B1 (en) 1999-08-20 2003-12-09 Isis Pharmaceuticals, Inc. Macrocyclic compounds and preparation methods thereof
US6951840B2 (en) 2001-08-31 2005-10-04 Eli Lilly And Company Lipoglycopeptide antibiotics
DE10226921A1 (de) 2002-06-17 2003-12-24 Bayer Ag Antibakterielle Amid-Makrozyklen
EP1656390A2 (en) 2003-07-17 2006-05-17 Migenix Inc. Compositions of lipopeptide antibiotic derivatives and methods of use thereof
DE10358824A1 (de) 2003-12-16 2005-07-21 Bayer Healthcare Ag Antibakterielle Makrozyklen mit substituiertem Biphenyl
DE102005014245A1 (de) 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Antibakterielle Amid-Makrozyklen V
DE102005014247A1 (de) 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Antibakterielle Amid-Makrozyklen VI
KR20130044382A (ko) 2010-03-01 2013-05-02 마이렉시스 인코포레이티드 화합물 및 그의 치료 용도
MX2012010381A (es) 2010-03-09 2012-11-23 Merck Canada Inc Lipoglicopeptidos en puente que potencian la actividad de antibacterianos de beta-lactama.
WO2011120071A1 (en) 2010-04-01 2011-10-06 The University Of Queensland Oxytocin peptide analogues
EP2616093A4 (en) 2010-09-15 2014-02-26 Scripps Research Inst IN A WIDE SPECTRUM ANTIBIOTIC ARYLOMYCIN ANALOGUE
WO2012166665A2 (en) 2011-05-27 2012-12-06 Rqx Pharmaceuticals, Inc. Broad spectrum antibiotics
US10501493B2 (en) 2011-05-27 2019-12-10 Rqx Pharmaceuticals, Inc. Broad spectrum antibiotics
CN103159830B (zh) 2011-12-15 2017-06-20 上海来益生物药物研究开发中心有限责任公司 脂肽类化合物
FR2986154B1 (fr) 2012-01-31 2017-08-04 Pierre Fabre Dermo-Cosmetique Nouveau systeme photoprotecteur
US20150045286A1 (en) * 2012-03-14 2015-02-12 The Scripps Research Institute Broad spectrum antibiotic arylomycin analogs
CN103788176A (zh) 2012-10-31 2014-05-14 上海来益生物药物研究开发中心有限责任公司 一种arylomycin类化合物及其制备方法和应用
JP6437443B2 (ja) 2012-11-21 2018-12-12 アールキューエックス ファーマシューティカルズ，インク． 大環状広域抗生物質
CN106661084B (zh) * 2014-05-20 2021-08-31 阿奇克斯制药公司 大环广谱抗生素
ITUB20154591A1 (it) 2015-10-12 2017-04-12 Crestoptics S R L Apparato di microscopia confocale e relativo procedimento di acquisizione ed elaborazione di immagini
TWI725075B (zh) 2015-11-20 2021-04-21 美商Ｒｑｘ製藥公司 巨環廣效抗生素
JP6873993B2 (ja) * 2015-11-20 2021-05-19 アールキューエックス ファーマシューティカルズ，インク． 大環状広域抗生物質
IL268483B2 (en) 2017-02-15 2024-02-01 Rqx Pharmaceuticals Inc A macrocyclic antibiotic with a broad spectrum
MX2019011517A (es) 2017-03-27 2019-11-18 Hoffmann La Roche Proceso para producir analogos de anillo de arilomicina.
MA50664A (fr) 2017-09-29 2020-08-05 Genentech Inc Complexes d'antibiotiques peptidiques et leurs méthodes d'utilisation

Also Published As

Publication number Publication date
IL295889A (en) 2022-10-01
PE20230383A1 (es) 2023-03-06
HUE063847T2 (hu) 2024-02-28
RS64852B1 (sr) 2023-12-29
LT3968983T (lt) 2023-10-10
TWI815017B (zh) 2023-09-11
KR20220003629A (ko) 2022-01-10
AU2020282975A1 (en) 2022-01-20
DK3968983T3 (da) 2023-10-30
MA55981A (fr) 2022-03-23
AU2023200369A1 (en) 2023-02-23
KR20220137165A (ko) 2022-10-11
IL288294A (en) 2022-01-01
MX2021014554A (es) 2022-03-17
TW202404953A (zh) 2024-02-01
CN115215923A (zh) 2022-10-21
JP2022525693A (ja) 2022-05-18
CA3141853A1 (en) 2020-12-03
ES2961566T3 (es) 2024-03-12
SI3968983T1 (sl) 2023-11-30
PT3968983T (pt) 2023-10-04
HRP20231497T1 (hr) 2024-03-01
EP3968983B1 (en) 2023-09-13
US11208387B2 (en) 2021-12-28
EP4289480A3 (en) 2024-02-21
FI3968983T3 (fi) 2023-11-01
KR102450071B1 (ko) 2022-09-30
CR20210682A (es) 2022-06-02
EP3968983A1 (en) 2022-03-23
WO2020243155A1 (en) 2020-12-03
TW202110812A (zh) 2021-03-16
JP2022137011A (ja) 2022-09-21
AU2020282975B2 (en) 2023-02-02
US20220135528A1 (en) 2022-05-05
EP3968983A4 (en) 2022-06-22
PE20240066A1 (es) 2024-01-11
US20200377463A1 (en) 2020-12-03
CN114007605A (zh) 2022-02-01
CO2021017561A2 (es) 2022-01-17
AR119019A1 (es) 2021-11-17
JP7078807B2 (ja) 2022-05-31
IL288294B (en) 2022-09-01
MA55981B1 (fr) 2024-02-29
CN114007605B (zh) 2022-07-15
PL3968983T3 (pl) 2024-03-18
BR112021024010A2 (pt) 2022-05-17
NZ783605A (en) 2022-08-26
EP4289480A2 (en) 2023-12-13
SG11202112920SA (en) 2021-12-30

Similar Documents

Publication Publication Date Title
CL2021003153A1 (es) Antibióticos macrocíclicos de amplio espectro
MX2016015218A (es) Antibioticos macrociclicos de amplio espectro.
CO2019010001A2 (es) Antibióticos macrociclicos de amplio espectro
MX2022006525A (es) Activo de polipeptidos de lisina contra bacterias gram-negativas.
MX2018006190A (es) Antibioticos de amplio espectro macrociclico.
UY30030A1 (es) Derivados sustituidos de la 8-piracin-2-il-1,2,4,4a-tetrahidro-2´h, 6h-espiro (1,4-oxacin(4,3-a)quinolin-5,5´-pirimidin)-2´, 4´, 6´ (1´h, 3´h)-tiona, composiciones y aplicaciones
MX2018006199A (es) Antibioticos de amplio espectro macrociclico.
EA200600280A1 (ru) Композиции на основе производных липопептидных антибиотиков и способы их применения
EA201590871A1 (ru) Макроциклические антибиотики широкого спектра действия
ATE452138T1 (de) Antibakterielle peptide und analoga davon
WO2017218922A8 (en) Compositions and methods for the treatment of bacterial infections
WO2015023898A8 (en) Linear peptide antibiotics
UY28542A1 (es) Amidas macrocíclicas antibacterianas
ATE510845T1 (de) Antibakterielle makrozyklen mit substituiertem biphenyl
WO2020014501A8 (en) Compositions and methods for the treatment of bacterial infections
WO2019067498A3 (en) Peptide antibiotic complexes and methods of use thereof
WO2015198265A3 (en) Disinfectant and antimicrobial compositions, in particular for the veterinary field
WO2004098500A3 (en) CARBACEPHEM ss-LACTAM ANTIBIOTICS
WO2021081110A3 (en) Peptides and use thereof
CL2021003592A1 (es) Compuestos y métodos de uso de los mismos como agentes antibacterianos.
UY31541A1 (es) 1(2)h-tetrazol-5-il-fenil-oxazolidinona s como agentes antibacterianos
CL2010001589A1 (es) Compuestos derivados de 3-ciano-pirrolidin-fenil-oxazolidinonas; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de infecciones bacterianas.
PL425328A1 (pl) Zastosowanie α,β-dihydroksantohumolu
WO2020014642A3 (en) Antibacterial peptide monomers and combinations for co-therapy
EA202190732A1 (ru) Антибактериальные соединения